Skip to main content


  • Poster presentation
  • Open Access

Predictors of immune reconstitution inflammatory syndrome associated with Kaposi sarcoma (IRIS-KS) in a rural area of Mozambique

  • 1,
  • 2,
  • 1,
  • 3,
  • 4,
  • 5,
  • 6,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of the International AIDS Society200811 (Suppl 1) :P288

  • Published:


  • Viral Load
  • Immune Reconstitution Inflammatory Syndrome
  • Human Herpesvirus
  • cART Initiation
  • Good Therapeutic Approach

Purpose of the study

IRIS-KS risk factors are not well known and their identification would aid in selection of the best therapeutic approach for high risk patients. The aim of this study was to identify risk factors for developing IRIS-KS among HIV and Human herpesvirus 8 (HHV-8) co-infected patients receiving cART in Mozambique.


This study was integrated into a larger prospective observational study conducted in the Manhiça Health Research Center, designed to characterize IRIS. The cohort described in the present study included those participants in the IRIS cohort with detectable anti-HHV-8 lytic antibodies or with KS at recruitment (n = 69). Plasma HIV viral load, CD4 and CD8 counts, immune activation, hepatic and renal function, WBC, RBC and platelet counts, anti-HHV-8 lytic antibodies and plasma and PBMC HHV-8 viral load were assessed at the pre-cART visit and at 4 months after cART initiation. Passive surveillance for potential IRIS-KS cases was performed throughout the study. A univariate and multivariate hazard analysis was carried out in order to assess potential risk factors for developing IRIS-KS among HHV-8 infected patients.

Summary of results

Thirteen patients presented with KS at the initial pre-cART visit and four additional patients were diagnosed with KS after cART initiation. Eight patients out of 69 (11.6%) experienced either an abrupt clinical worsening (four) or debuted with KS (four) with a median time of 13.8 weeks (IQR, 3–23) after cART initiation, in the context of a mean 2.58 log10 copies/mL (sd 0.2) decline in plasma HIV-RNA viral load and a median increase of 95 CD4+ cells/μl (IQR, 6–136) from pre-cART levels. Multivariate hazard analysis showed that, at pre-cART visit, a plasma HIV-RNA viral load>5 log10 copies/mL, a body mass index (BMI)<18.5 and the presence of KS were independently associated with the development of IRIS-KS. At 4 months after cART, IRIS-KS cases tended to have achieved a better HIV virologic control and a higher absolute change in anti-HHV-8 lytic antibodies than those HHV-8 infected patients that did not develop IRIS-KS. In order to better characterize the relation between HHV-8 and IRIS-KS, determination of HHV-8 DNA loads is currently underway.


In this cohort of antiretroviral-naïve HIV and HHV-8 co-infected African patients, IRIS-KS was observed in 11.6% of patients. A plasma HIV-1 RNA viral load>5 log10 copies/mL, a BMI<18.5, and the presence of KS at baseline were independent predictors of IRIS-KS. Close clinical supervision is warranted for these patients.

Authors’ Affiliations

Barcelona Centre for International Health Research, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigação em Saude de Manhiça, Manhiça, Mozambique
Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Department of Pathology, Hospital Central de Maputo, Maputo, Mozambique
Department of Dermatology, Hospital Central de Maputo, Maputo, Mozambique
Centro de Saude de Manhiça, Ministerio de Saude de Moçambique, Manhiça, Mozambique


  1. Leidner RS, Aboulafia DM: Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. 2005, 19 (10): 635-44. 10.1089/apc.2005.19.635.PubMedView ArticleGoogle Scholar
  2. El Amari EB, et al: Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS. 2008, 22 (9): 1019-28.PubMedView ArticleGoogle Scholar


© Letang et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.